JNJ - Johnson & Johnson
(NaN%)
SNP 500DOW 30
Hold
Moderate Growth and Improving
50%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 32.48%
Operating Income Growth is 62.24%
Net Income Growth is -57.59%
Earnings Per Share (EPS) Growth is -54.63%
Net Margin is 16.74%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.03
Debt Ratio is 0.61
Current Debt to Net Income Ratio is 1.66
Total Debt to Total Assets Ratio is 0.2
Cash Flow is STRONG
Cash from Operations Growth is 24.01%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Johnson & Johnson (JNJ) - https://www.jnj.com/
Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Alex Gorsky
Employees - 152,700
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.